The future of oncology biosimilars

Biologic's expiring patent cliff opens the door for biosimilars to increase treatment accessibility

There are an estimated 100 blockbuster drugs facing the biologics' patent cliff and losing patent protection over the next 15 years. The largest therapeutic cohort covers oncology treatments. 

This presents the developers of biosimilars, complex molecules that are highly comparable to their reference biologics i.e., generic drugs for biologics, with an opportunity to create drugs with an established market and patient population. It also opens up previously inaccessible markets, where the reference drug is unavailable for supply or affordability reasons.

Download the whitepaper to learn more about:                          

• The oncology biosimilars patent and market landscape
• Current regulatory requirements, biosimilar regulatory strategy and likely regulatory shifts
• Considerations for drug modalities such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and CAR T therapies
• Hurdles for biosimilar market access and strategies for encouraging biosimilar adoption and biosimilar interchangeability
• New technologies and methods in biosimilar post-market monitoring plus implications for biosimilar compliance requirements